Intravenous alteplase versus oral aspirin for acute central retinal artery occlusion within 4&#xb7;5 h of severe vision loss (THEIA): a multicentre, double-dummy, patient-blinded and assessor-blinded, randomised, controlled, phase 3 trial

Macular DiseasesRetinal Diseases

Impact of retinal thickness fluctuations with ranibizumab versus aflibercept in neovascular age-related macular degeneration (SALT): 12-month results from a multicentre, randomised, phase IV trial

Br J Ophthalmol

Agostini HT, Silva R, Holz FG, Larsen M, Altay L, Souied EH, Quiering C, Rose U, Liakopoulos S, SALT study group

doi: 10.1136/bjo-2024-326526

Lenses

Effect of daily disposable Defocus Incorporated Soft Contact lens on myopia control: a 1-year multicentre randomised controlled trial

Br J Ophthalmol

Liu L, Wang J, Tse DY, Zuo B, Song D, Du B, Chen Z, To CH, Chun RKM, Jiang J, Wei R

doi: 10.1136/bjo-2025-327471

Macular Diseases

Long-Term Efficacy and Safety of CT-P42 in Patients with Diabetic Macular Edema: 52-Week Results from a Phase 3 Randomized Clinical Trial

Ophthalmol Ther

Brown DM, Wolf S, Veselovsky M, Veith M, Papp A, Mange S, Mondal LK, Romanczak D, Janco L, Chauhan R, Romanowska-Dixon B, Eremina A, Dusova J, Sagong M, Kim S, Bae Y, Kim S, Bae Y, Son D, Kang H, Choi S, Stanga PE

doi: 10.1007/s40123-025-01197-w

Further Publications

3-year results of 0.01% and 0.1% loading dose atropine treatment including washout in Danish children with myopia: a placebo-controlled, randomised clinical trial

Br J Ophthalmol

Hansen N, Hvid-Hansen A, Møller F, Bek T, Larsen D, Jacobsen N, Kessel L

doi: 10.1136/bjo-2024-326918

Lenses

Efficacy of spectacle lenses for myopia control: a meta-analysis of randomised controlled trials

Br J Ophthalmol

D'Andrea L, Rinaldi M, Piscopo R, Iorio F, La Padula S, Maqsood S, Elalfy M, Melenzane A, Confalonieri F, Ozkan O, Utine CA, Costagliola C

doi: 10.1136/bjo-2025-327629

Macular Diseases

Visual Function Benefit After Treatment With Pegcetacoplan: Microperimetry Analysis From The Phase 3 Oaks Trial: Microperimetry: Visual Function Benefit With Pegcetacoplan

Am J Ophthalmol

Chakravarthy U, Schwartz R, Guymer RH, Holz FG, Rachitskaya AV, Vujosevic S, Lewis P, Vorwerk H, Alibhai AY, Moult EM, Morales MU, Bliss C, Baumal CR, Waheed NK

doi: 10.1016/j.ajo.2025.02.012

Macular DiseasesRetinal Diseases

Faricimab Treat-and-Extend Dosing for Macular Edema due to Retinal Vein Occlusion: 72-Week Results From the BALATON and COMINO Trials

Ophthalmol Retina

Danzig CJ, Dinah C, Ghanchi F, Hattenbach LO, Khanani AM, Lai TYY, Shimura M, Abreu F, Arrisi P, Liu Y, Paris LP, Retiere AC, Willis JR, Schlottmann PG, BALATON and COMINO Investigators

doi: 10.1016/j.oret.2025.03.005

Lenses

Atropine and Spectacle lens Combination Treatment (ASPECT): 12-month results of a randomised controlled trial for myopia control using a combination of Defocus Incorporated Multiple Segments (DIMS) lenses and 0.025% atropine

Br J Ophthalmol

Guemes-Villahoz N, Talavero González P, Porras-Ángel P, Bella-Gala R, Ruiz-Pomeda A, Martin-Garcia B, Hernandez-Garcia E, Gomez de Liaño N, Shah R, Garcia-Feijoo J, Gomez-de-Liaño R

doi: 10.1136/bjo-2024-326852

Macular Diseases

Intravitreal Aflibercept 8 mg in Neovascular Age-related Macular Degeneration: 96-Week Results from the Randomized Phase 3 PULSAR Trial

Ophthalmology

Korobelnik JF, Lanzetta P, Leal S, Holz FG, Clark WL, Eichenbaum D, Iida T, Sun X, Berliner AJ, Schulze A, Zhao M, Schmelter T, Schmidt-Ott U, Zhang X, Morgan-Warren P, Hasanbasic Z, Vitti R, Chu KW, Reed K, Bhore R, Cheng Y, Bai Z, Hirshberg B, Yancopoulos GD, Wong TY, PULSAR investigators

doi: 10.1016/j.ophtha.2025.08.022

Related content

Impact of retinal thickness fluctuations with ranibizumab versus aflibercept in neovascular age-related macular degeneration (SALT): 12-month results from a multicentre, randomised, phase IV trial

Effect of daily disposable Defocus Incorporated Soft Contact lens on myopia control: a 1-year multicentre randomised controlled trial

Long-Term Efficacy and Safety of CT-P42 in Patients with Diabetic Macular Edema: 52-Week Results from a Phase 3 Randomized Clinical Trial

3-year results of 0.01% and 0.1% loading dose atropine treatment including washout in Danish children with myopia: a placebo-controlled, randomised clinical trial

Efficacy of spectacle lenses for myopia control: a meta-analysis of randomised controlled trials

Visual Function Benefit After Treatment With Pegcetacoplan: Microperimetry Analysis From The Phase 3 Oaks Trial: Microperimetry: Visual Function Benefit With Pegcetacoplan

Faricimab Treat-and-Extend Dosing for Macular Edema due to Retinal Vein Occlusion: 72-Week Results From the BALATON and COMINO Trials

Atropine and Spectacle lens Combination Treatment (ASPECT): 12-month results of a randomised controlled trial for myopia control using a combination of Defocus Incorporated Multiple Segments (DIMS) lenses and 0.025% atropine

Intravitreal Aflibercept 8 mg in Neovascular Age-related Macular Degeneration: 96-Week Results from the Randomized Phase 3 PULSAR Trial